Pooled analysis of the CYP1A1 exon 7 polymorphism and lung cancer (United States)

Cancer Causes and Control

Volumn 14, Issue 4, 2003, Pages 339-346

  Le Marchand, Loïc ^a   Guo, Chuanfa ^a   Benhamou, Simone ^b   Bouchardy, Christine ^k   Cascorbi, Ingolf ^c   Clapper, Margie L ^d   Garte, Seymour ^e   Haugen, Aage ^g   Ingelman Sundberg, Magnus ^g   Kihara, Masahiro ^h   Rannug, Agneta ^g   Ryberg, David ^f   Stücker, Isabelle ^b   Sugimura, Haruhiko ⁱ   Taioli, Emanuela ^j  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b INSERM   (France)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d FOX CHASE CANCER CENTER   (United States)

^e Genetics Research Institute   (Italy)

^f NATIONAL INSTITUTE OF OCCUPATIONAL HEALTH   (Norway)

^g KAROLINSKA INSTITUTE   (Sweden)

^h KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

ⁱ HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^k Ospedale Maggiore IRCCS ^*

more..

Author keywords

CYP1A1; Lung neoplasm; Pooled analysis; Race; Sex; Smoking

Indexed keywords

CYTOCHROME P450;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; ASIAN; CAUCASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; DNA POLYMORPHISM; EXON; FEMALE; GENE DOSAGE; GENETIC ANALYSIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZATION; SEX DIFFERENCE; SMOKING; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; AGED; CARCINOGENS, ENVIRONMENTAL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 CYP1A1; EXONS; FEMALE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; RISK FACTORS; SEX FACTORS; SMOKING; UNITED STATES;

EID: 0037701670     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023956201228     Document Type: Article

References (46)

1. Guengerich FP, Shimada T (1998) Activation of procarcinogens by human cytochrome P450 enzymes. Mutat Res 400: 201-213.
2. Butler JP, Post GB, Lioy PJ, Waldman JM, Greenberg A (1993) Assessment of carcinogenic risk from personal exposure to benzo[α]pyrene in the total human environmental exposure study (THEES). J Air Waste Manag Assoc 43: 970-977.
3. Kawajiri K, Nakachi K, Imai K, Shimoda N, Watanabe J (1990) Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Lett 263: 131-133.
4. Hayashi S, Watanabe J, Nakachi K, Kawajiri K (1991) Genetic linkage of lung cancer-associated MspI polymorphism with amino acid replacement in the hem binding region of the human cytochrome P4501A1 gene. J Biochem 110: 407-411.
5. Cascorbi I, Brockmoller J, Roots I (]996) A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 56: 4965-4969.
6. Crofts F, Cosma GN, Currie D, Taioli E, Toniolo P, Garte SJ (1993) A novel CYP1A1 gene polymorphism in African-Americans. Carcinogenesis 14: 1729-1731.
7. Landi MT, Bertazzi PA, Shields PG, et al. (1994) Association between CYP1A genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 4: 242-246.
8. Crofts F, Taioli E, Trachman J, et al. (1994) Functional significance of different human CYP1A1 genotypes. Carcinogenesis 15: 2961-2963.
9. Kiyohara C, Hirohata T, Inutsuka S (1996) The relationship between ary1 hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene. Jpn J Cancer Res 87: 18-24.
10. Nerurkar PV, Okinaka L, Aoki C, et al. (2000) CYP1A1, GSTM1, and GSTP1 genetic polymorphisms an urinary 1-hydroxypyrene excretion in non-occupationally exposed individuals. Cancer Epidemiol Biomarkers Prev 9: 1119-1122.
11. Bartsch H, Nair U, Risch A, Rojas M, Wikman H, Alexandrov K (2000) Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 9: 3-28.
12. Taioli E (1999) International collaborative study on genetic susceptibility to environmental carcinogens. Cancer Epidemiol Biomarkers Prev 8: 727-728.
13. Anttila S, Lei X-D, Elovaara E, et al. (2000) An uncommon phenotype of poor inducibility of CYP1A1 in human lung is not ascribable to polymorphisms in the AHR, ARNT, or CYP1A1 genes. Pharmacogeneties 10: 741-751.
14. Shields PG, Caporaso NE, Falk RT, et al. (1993) Lung cancer, race, and a CYP1A1 genetic polymorphism. Cancer Epidemiol Biomarkers Prev 2: 481-485.
15. Dolzan V, Rudolf Z, Breskvar K (2000) Genetic polymorphism of xenobiotic metabolizing enzymes in Slovenian lung cancer patients. Pflugers Arch 439(3 Suppl): R29-R30.
16. Hirvonen A, Husgafvel-Pursiainen K, Anttila S, Karjalainen A, Vainio H (1992) Point-mutational MspI and Ile-Val polymorphisms closely linked in the CYPIAI gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol Biomarkers Prev 1: 485-489.
17. Breslow NE, Day NE (1980) Statistical Methods in Cancer Research. Vol. I. The Analysis of Case-control Studies. IARC Scientific Pub. No. 32. Lyon: International Agency for Research on Cancer.
18. Fleiss JL (1993) The statistical basis of meta-analysis. Stat Meth Med Res 2: 121-145.
19. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
20. Friedenreich CM (1993) Methods for pooled analysis of epidemiologic studies. Epidemiology 4: 295-302.
21. Sham P (1998) Statistics in Human Genetics. London: Arnold Publishers.
22. Sugimura H, Wakai K, Genka K, et al. (1998) Association of Ile462Val (exon 7) polymorphism of cytochrome P450 IA1 with lung cancer in the Asian population: further evidence from a case-control study in Okinawa. Cancer Epidemiol Biomarkers Prev 7: 413-417.
23. Bau EJ (1978) Occurrence and surveillance of polycyclic aromatic hydrocarbons. In: Gelboin HV, Ts'o POP, eds. Polycyclic Hydrocarbons and Cancer. New York Academic Press, pp. 45-70.
24. Sabadie N, Richter-Reichhelm HB, Saracci R, Mohr U, Bartsch H (1981) Interindividual differences in oxidative benzo(α)pyrene metabolism by normal and tumorous surgical lung specimens form 105 lung cancer patients. Int J Cancer 41: 417-425.
25. Novak D, Schmidt-Preuss U, Jorres R, Liebke F, Rudiger HW (1988) Formation of DNA adducts and water-soluble metabolites of benzo (α) pyrene in human monocytes is genetically controlled. Int J Cancer 41: 169-173.
26. McLemore TL, Adelberg A, Liu MC, et al. (1990) Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 82: 1333-1339.
27. Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL (1982) Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved/ymphocytes. Cancer Res 42: 5030-5037.
28. Law MR (1990) Genetic predisposition to lung cancer. Br J Cancer 61: 195-206.
29. Wu M-T, Huang S-L, Ho C-K, Yeh Y-F, Christiani DC (1998) Cytochrome p450 1 A1 MspI polymorphism and urinary 1-hydroxypyrene concentrations in coke oven workers. Cancer Epidemiol Biomarkers Prev 7: 823-829.
30. Merlo F, Andreassen A, Weston A, et al. (1998) Urinary excretion of 1-hydroxypyrene as a marker for exposure to urban air levels of polycyclic aromatic hydrocarbons. Cancer Epidemiol Biomarkers Prev 7: 147-155.
31. Mooney LA, Bell DA, Santella RS, et al. (1997) Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis (Lond) 18: 503-509.
32. Le Marchand L, Sivaraman L, Pierce L, et al. (1998) Associations of CYP1AI, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 58: 4858-4863.
33. Okada T, Kawashima K, Fukushi S, Minakuchi T, Nishimura S (1994) Association between a cytochrome P4501A1 genotype and incidence of lung cancer. Pharmacogenetics 4: 333-340.
34. Dresler CM, Fratelli C, Babb J, Everley L, Evans AA, Clapper ML (2000) Gender differences in genetic susceptibility for lung cancer. Lung Cancer 30: 53-160.
35. Shields PG, Caporaso NE, Falk RT, et al. (1993) Lung cancer, race, and a CYP1AI genetic polymorphism. Cancer Epidemiol Biomarkers Prev 2: 481-489.
36. Drakoulis N, Cascorbi I, Brockmoller J, Gross CR, Roots I (1994) Polymorphisms in the human CYP1AI gene as susceptibility factors to lung cancer: exon 7 mutation (4889 A to G) and a T to C mutation in the 3′-flanking region. Clin Investig 72: 240-248.
37. Xu X, Kelsey KT, Wiencke JK, Wain JC, Christiani DC (1996) Cytochrome P450 CYPIA1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 5: 687-692.
38. Nakachi K, Imai K, Hayashi S-I, Kawajiri K (1993) Polymorphisms to the CYPIA1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res 53: 2994-2999.
39. Ishibe N, Wiencke JK, Zuo Z-F, McMillan A, Spitz M, Kelsey KT (1997) Susceptibility to lung cancer in light smokers associated with CYP1A1 polymorphisms in Mexican- and African-Americans. Cancer Epidemiol Biomarkers Prev 6: 1075-1080.
40. Houlston RS (2000) CYP1A1 polymorphisms and lung cancer risk: a meta-analySis. Pharmacogeneties 10: 105-114.
41. Kihara M, Kihara M, Noda K (1995) Risk of smoking for squamous cell and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. Carcinogenesis 16: 2331-2336.
42. Alexandrie A-K, Ingelman Sundberg M, Seidegard J, Tornling G, Rannug A (1994) Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTMI: a study on host factors in relation to age at onset, gender and histological cancer types. Carcinogenesis 15: 1785-1790.
43. Persson I, Johansson I, Lou Y-C, et al. (1999) Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. Int J Cancer 81: 325-329.
44. Taioli E, Ford J, Trachman J, Li Y, Demopoulos R, Garte S (1998) Lung cancer risk and CYP1A1 genotype in African Americans. Carcinogenesis 19: 813-817.
45. Bouchardy C, Wilkman H, Benhamou S, Hirvonen A, Dayer P, Husgafvel-Pursiainen K (1997) CYP1A1 genetic polymorphisms, tobacco smoking and lung cancer risk in a French Caucasian population. Biomarkers 2: 131-134.
46. 1450) gene: lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1: 20-25.